Spyre Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed October 9, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Fairmount Funds Management LLC filed an amended Schedule 13D/A regarding beneficial ownership in Spyre Therapeutics, Inc. (public market value ~$1.1B). The filing document header and metadata are present, but the specific amendments—share count, percentage ownership, transaction details, dates, and what changed from the prior disclosure—are not provided in the text excerpt supplied.
Why this rating
Amendment to ownership disclosure; specifics absent. Routine SEC filing unless amendment reveals major stake change or intent shift.
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.